May 5, 2015

GastroPlus Version 9.0 is released! New: Biologics, Dermal, ADMET Predictor Integration

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has released the long-awaited Version 9.0 of its flagship GastroPlus™ simulation software.

Dr. Michael Bolger, chief scientist of Simulations Plus, said: "We’re very pleased to announce the release of GastroPlus Version 9.0. This is the largest single upgrade we’ve made to the program to date, and the level of science and technology adds valuable new functionalities that we believe will provide the most advanced decision-making tool for preclinical and early clinical trial simulation and modeling analysis available today. Several of the significant enhancements include:

  • ability to simulate the absorption and distribution of biologics (antibodies and proteins)
  • ability to simulate dosing to the skin, including patches, creams, ointments, and subcutaneous injections
  • tighter integration with our ADMET Predictor™ software to increase the utility of the program in early drug discovery."

Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added: “GastroPlus is all about integrating the best science into user-friendly software to enable pharmaceutical researchers and regulators to perform sophisticated analyses of complex drug behaviors in humans and laboratory animals. Already the most widely used program in the world for physiologically based pharmacokinetics (PBPK), the addition of these new capabilities is expected to expand the user base earlier into the research & development process within the pharmaceutical industry, while also helping us further penetrate the biopharmaceuticals, food, cosmetics, and general toxicology markets.”

Dr. Ted Grasela, president of Simulations Plus and its wholly owned subsidiary, Cognigen Corporation, said, “The release of GastroPlus 9.0 is the culmination of many months of hard work by Dr. Viera Lukacova and her Simulation Technologies team, supported by a large number of other scientists and engineers within Simulations Plus. Some of our customers have been using portions of the new features for over a year and have provided valuable feedback to improve the code. We’re excited about the possibilities that this new release brings and how it can further increase the efficiency of model-based drug development.”

About Simulations Plus, Inc. and Cognigen Corp.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus also recently acquired Cognigen Corporation of Buffalo, NY, adding to our offerings top-quality statistical modeling and simulation using clinical trial data, as well as more than doubling our staff from 30 to over 60, adding nearly 50% to revenues, and increasing earnings in the fiscal year that began September 1, 2014. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp is located in Buffalo, New York. For more information, visit our Web site at http://www.simulations-plus.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.">www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.     

 

You have chosen to email the article entitled:

GastroPlus Version 9.0 is released! New: Biologics, Dermal, ADMET Predictor Integration

Your Name:     * Your Email:    *

Friends Name: * Friends Email: *

Comments:

Please enter the word you see in the image below:

*

  

* = Required Field

Commenting is not available for this article.